Target attainment of intravenous lefamulin for treatment of acute bacterial skin and skin structure infections.
Wisse Van OsMarkus ZeitlingerPublished in: The Journal of antimicrobial chemotherapy (2024)
Lefamulin at the currently approved IV dosage covers most Staphylococcus aureus isolates when targeting drug exposure associated with bacteriostasis, suggesting potential of lefamulin for the treatment of ABSSSIs. Lefamulin may not be appropriate in ABSSSI when rapid bactericidal activity is warranted.
Keyphrases
- staphylococcus aureus
- emergency department
- liver failure
- high dose
- escherichia coli
- wound healing
- intensive care unit
- risk assessment
- pseudomonas aeruginosa
- low dose
- extracorporeal membrane oxygenation
- respiratory failure
- replacement therapy
- electronic health record
- methicillin resistant staphylococcus aureus
- smoking cessation